PLRX · Pliant Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $0 | $0 | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $13.58M | - | $17.94M | $32.20M | $43.44M | - | $47.75M | $45.62M | $37.15M | - |
| SG&A | $8.19M | - | $10.33M | $13.39M | $15.50M | - | $14.26M | $15.02M | $15.25M | - |
| Total Operating Expenses | $21.77M | - | $28.27M | $45.59M | $58.94M | - | $62.01M | $60.64M | $52.39M | - |
| D&A | $264.0K | - | $400.0K | $400.0K | $448.0K | - | $500.0K | $600.0K | $513.0K | - |
| Operating Income | ($21.77M) | - | ($28.27M) | ($45.59M) | ($58.94M) | - | ($62.01M) | ($60.64M) | ($52.39M) | - |
| Interest Expense | $0 | - | $815.0K | $809.0K | $445.0K | - | $877.0K | $319.0K | $445.0K | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($20.04M) | - | ($26.30M) | ($43.30M) | ($56.17M) | - | ($57.76M) | ($55.85M) | ($46.95M) | - |
| EPS - Basic | ($0.32) | - | ($0.43) | ($0.71) | ($0.92) | - | ($0.95) | ($0.92) | ($0.78) | - |
| EPS - Diluted | ($0.32) | - | ($0.43) | ($0.71) | ($0.92) | - | ($0.95) | ($0.92) | ($0.78) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.19M | $45.45M | $93.73M | $86.82M | $91.94M | $71.19M | $79.62M | $80.39M | $114.30M | $63.23M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | $0 |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $362.0K | $480.0K | $485.0K | $1.38M | $5.62M | $5.96M | $6.89M | $3.25M | $7.33M | $4.53M |
| Current Assets | $174.93M | $196.45M | $245.59M | $267.44M | $311.19M | $362.26M | $410.03M | $447.55M | $489.90M | $505.50M |
| Total Assets | $202.60M | $225.23M | $276.60M | $299.82M | $344.77M | $396.95M | $445.67M | $483.73M | $521.61M | $512.15M |
| Current Liabilities | $10.36M | $16.36M | $17.62M | $20.59M | $28.20M | $33.22M | $39.95M | $30.92M | $30.39M | $28.52M |
| Long-term Debt | $0 | $0 | $30.44M | $30.36M | $30.28M | $30.21M | $30.14M | $30.07M | $30.00M | $10.05M |
| Total Liabilities | $37.43M | $44.02M | $76.29M | $79.74M | $87.61M | $92.87M | $99.84M | $91.05M | $84.27M | $38.58M |
| Stockholders' Equity | $165.17M | $181.21M | $200.31M | $220.08M | $257.16M | $304.08M | $345.82M | $392.68M | $437.33M | $473.58M |
| Retained Earnings | ($879.44M) | ($859.40M) | ($835.82M) | ($809.52M) | ($766.22M) | ($710.05M) | ($660.32M) | ($602.56M) | ($546.70M) | ($499.75M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($19.23M) | - | - | - | ($48.86M) | - | - | - | ($30.27M) | - |
| Investing Cash Flow | ($4.10M) | - | - | - | $69.11M | - | - | - | $59.55M | - |
| Financing Cash Flow | $74.0K | - | - | - | $498.0K | - | - | - | $21.79M | - |
| CapEx | $0 | - | - | - | $262.0K | - | - | - | $1.49M | - |
| Free Cash Flow | ($19.23M) | - | - | - | ($49.13M) | - | - | - | ($31.76M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.96 | - | - | - | 0.87 | - | - | - | 0.68 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.9% | - | -9.5% | -14.4% | -16.3% | - | -13.0% | -11.5% | -9.0% | - |
| Return on equity | -12.1% | - | -13.1% | -19.7% | -21.8% | - | -16.7% | -14.2% | -10.7% | - |
| Return on invested capital | -10.4% | - | -9.7% | -14.4% | -16.2% | - | -13.0% | -11.3% | -8.9% | - |
| Liquidity | ||||||||||
| Current ratio | 16.89 | 12.00 | 13.93 | 12.99 | 11.03 | 10.91 | 10.26 | 14.47 | 16.12 | 17.72 |
| Quick ratio | 16.89 | 12.00 | 13.93 | 12.99 | 11.03 | 10.91 | 10.26 | 14.47 | 16.12 | 17.72 |
| Cash ratio | 2.14 | 2.78 | 5.32 | 4.22 | 3.26 | 2.14 | 1.99 | 2.60 | 3.76 | 2.22 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.00 | 0.15 | 0.14 | 0.12 | 0.10 | 0.09 | 0.08 | 0.07 | 0.02 |
| Debt / Assets | 0.00 | 0.00 | 0.11 | 0.10 | 0.09 | 0.08 | 0.07 | 0.06 | 0.06 | 0.02 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -34.7x | -56.4x | -132.4x | - | -70.7x | -190.1x | -117.7x | - |
| Equity multiplier | 1.23 | 1.24 | 1.38 | 1.36 | 1.34 | 1.31 | 1.29 | 1.23 | 1.19 | 1.08 |
| Liabilities / Assets | 0.18 | 0.20 | 0.28 | 0.27 | 0.25 | 0.23 | 0.22 | 0.19 | 0.16 | 0.08 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.5x | - | 0.5x | 0.3x | 0.3x | - | 2.0x | 1.7x | 2.1x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | -100.0% | -100.0% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 63.1% | - | 54.4% | 24.8% | -12.5% | - | -30.0% | -28.1% | -24.5% | - |
| Net income growth (YoY) | 64.3% | - | 54.5% | 22.5% | -19.6% | - | -39.2% | -35.6% | -25.1% | - |
| EPS growth (YoY) | 65.2% | - | 54.7% | 22.8% | -17.9% | - | -35.7% | -31.4% | -16.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 60.9% | - | - | - | -54.7% | - | - | - | -4.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -35.8% | -40.4% | -42.1% | -44.0% | -41.2% | -35.8% | -31.3% | -26.3% | -22.2% | 51.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Business segments
$1.58M totalReportable Segment$1.58M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing PLIANT THERAPEUTICS against the 5 most active filers in the same SIC group.